Text Size

The Efficacy of Selective Laser Trabeculoplasty

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2006 by Glaucoma Research & Education Group.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
PharmaLogic Development, Inc.
Information provided by:
Glaucoma Research & Education Group
ClinicalTrials.gov Identifier:
NCT00347893
First received: June 30, 2006
Last updated: NA
Last verified: June 2006
History: No changes posted
  Purpose

Selective laser trabeculoplasty (SLT) is a new method to reduce intraocular pressure in eyes with open angle glaucoma or ocular hypertension. SLT may also be effective for cases with previously failed ALT procedures. We will study the efficacy and safety of the SLT procedure.


Condition Intervention
Primary Open Angle Glaucoma
Ocular Hypertension
Pseudo-Exfoliative Glaucoma
Pigment Dispersion Glaucoma
 Procedure: Selective laser trabeculoplasty

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Retrospective
Official Title: Clinical Results of Selective Laser Trabeculoplasty in Treatment of Open Angle Glaucoma

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Glaucoma Research & Education Group:

Study Start Date: May 2006
Detailed Description:

Selective laser trabeculoplasty (SLT) has been shown to be a safe, well tolerated, and effective intraocular pressure reduction therapy for several forms of open-angle glaucoma. SLT produces significantly less disturbance to the trabecular meshwork and is theoretically more repeatable than the ALT procedure. This retrospective research will begin with cases treated in 2001. It will evaluate whether SLT is effective for patients who have had prior treatment with ALT and it will determine whether the IOP lowering effect is sustainable over time. It will also assess the efficacy of repeated SLT procedures.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients with primary open angle glaucoma, ocular hypertension, pseudo exfoliative glaucoma, pigment dispersion glaucoma

Exclusion Criteria:

  • History of prior invasive glaucoma surgery
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00347893

Locations
United States, California
Glaucoma Center of San Francisco Recruiting
San Francisco, California, United States, 94105
Contact: Martha T Klufas, OD     415-986-0835     martha@glaucomagroup.org    
Principal Investigator: Andew G. Iwach, M.D.            
Sub-Investigator: Jing Ming Shi, M.D.            
Sub-Investigator: Terri Pickering, M.D.            
Sponsors and Collaborators
Glaucoma Research & Education Group
PharmaLogic Development, Inc.
Investigators
Principal Investigator: Andrew G. Iwach, M.D. Glaucoma Research & Education Group
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00347893     History of Changes
Other Study ID Numbers: 22222
Study First Received: June 30, 2006
Last Updated: June 30, 2006
Health Authority: United States: Institutional Review Board

Keywords provided by Glaucoma Research & Education Group:
Primary open angle glaucoma
Ocular hypertension
Pseudo-exfoliative glaucoma
 Pigment Dispersion glaucoma
selective laser trabeculoplasty
intraocular pressure

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Open-Angle
Hypertension
Ocular Hypertension
 Eye Diseases
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on June 17, 2013